Plasma kallikrein: Novel functions for an old protease

Thrombosis and Haemostasis

Volumn 107, Issue 6, 2012, Pages 1012-1013

  Renné, Thomas ^a   Gruber, András ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVITAMIN K; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 12; BRADYKININ; COMPLEMENT COMPONENT C1S INHIBITOR; DABIGATRAN ETEXILATE; FONDAPARINUX; HEPARIN; HIGH MOLECULAR WEIGHT KININOGEN; PLASMA KALLIKREIN; RIVAROXABAN; WARFARIN;

ANTICOAGULANT THERAPY; BLEEDING; BLOOD CLOTTING; EDITORIAL; FIBRIN FORMATION; HUMAN; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTEIN FUNCTION; THROMBOSIS;

ANIMALS; HEMOSTASIS; PLASMA KALLIKREIN; PREKALLIKREIN; THROMBOSIS;

EID: 84861735451     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH12-04-0264     Document Type: Editorial

References (18)

1. Bird J.E, Smith P, Wang X, et al. Effects of Plasma Kallikrein Deficiency on Haemostasis and Thrombosis in Mice: Murine Ortholog of Fletcher Trait. Thromb Haemost 2012; 107: 1141-1150.
2. Renne T. The procoagulant and proinflammatory plasma contact system. Semin Immunopathol 2012; 34: 31-41.
3. Muller F, Renne T. Novel roles for factor XII-driven plasma contact activation system. Curr Opin He-matol 2008; 15: 516-521.
4. Leeb-Lundberg LM, Marceau F, Muller-Esterl W, et al. Classification of the Kinin Receptor Family: from Molecular Mechanisms to Pathophysiological Consequences. Pharmacol Rev 2005; 57: 27-77.
5. Liu J, Gao BB, Clermont AC, et al. Hyperglycemia-induced cerebral hematoma expansion is mediated by plasma kallikrein. Nat Med 2011; 17: 206-210.
6. Saito H. Studies on Fletcher trait and Fitzgerald trait. A rare chance to disclose body's defense reactions against injury. Thromb Haemost 2010; 104: 867-874.
7. Chung DW, Fujikawa K, McMullen BA, et al. Human plasma prekallikrein, a zymogen to a serine protease that contains four tandem repeats. Biochemistry 1986; 25: 2410-2417.
8. McMullen BA, Fujikawa K, Davie EW. Location of the disulfide bonds in human plasma prekallikrein: the presence of four novel apple domains in the amino-terminal portion of the molecule. Biochemistry 1991; 30: 2050-2056.
9. Pauer HU, Renne T, Hemmerlein B, et al. Targeted deletion of murine coagulation factor XII gene-a model for contact phase activation in vivo. Thromb Haemost 2004; 92: 503-508.
10. Iwaki T, Cruz-Topete D, Castellino FJ. A complete factor XII deficiency does not affect coagulopathy, inflammatory responses, and lethality, but attenuates early hypotension in endotoxemic mice. J Thromb Haemost 2008; 6: 1993-1995.
11. Renne T, Pozgajova M, Gruner S, et al. Defective thrombus formation in mice lacking coagulation factor XII. J Exp Med 2005; 202: 271-281.
12. Wang X, Smith PL, Hsu MY, et al. Effects of factor XI deficiency on ferric chloride-induced vena cava thrombosis in mice. J Thromb Haemost 2006; 4: 1982-1988.
13. Cheng Q, Tucker EI, Pine MS, et al. A role for factor XIIa-mediated factor XI activation in thrombus formation in vivo. Blood 2010; 116: 3981-3989.
14. Merkulov S, Zhang WM, Komar AA, et al. Deletion of murine kininogen gene 1 (mKng1) causes loss of plasma kininogen and delays thrombosis. Blood 2008; 111: 1274-1281.
15. Muller F, Gailani D, Renne T. Factor XI and XII as antithrombotic targets. Curr Opin Hematol 2011; 18: 349-355.
16. Seligsohn U. Factor XI deficiency in humans. J Thromb Haemost 2009; 7 (Suppl 1): 84-87.
17. Girolami A, Scarparo P, Candeo N, et al. Congenital prekallikrein deficiency. Expert Rev Hematol 2010; 3: 685-695.
18. Weitz JI. Factor Xa and thrombin as targets for new oral anticoagulants. Thromb Res 2011; 127 (Suppl 2): S5-S12.